Active Ingredient(s): Decitabine
FDA Approved: * May 2, 2006
Pharm Company: * MGI PHARMA INC
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Dacogen Overview

Decitabine, sold under the brand name Dacogen, acts as a nucleic acid synthesis inhibitor.[1] It is a medication for the treatment of myelodysplastic syndromes, a class of conditions where certain blood cells are dysfunctional, and for acute myeloid leukemia (AML).[2] Chemically, it is a cytidine analog. Contents 1 Medical uses 2 Pharmacology 3 Research 3.1 Atherosclerosis 4 References 5 Further reading 6 External links Medical uses Decitabine is used...

Read more Dacogen Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Decitabine

Recent Dacogen Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 15m/m(2), 50mg, 50mg/vial
  • Powder: 50mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Dacogen: (2 results)

Sorted by National Drug Code
  • 59148-046 Dacogen 50 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution by Otsuka America Pharmaceutical, Inc.
  • 62856-600 Dacogen 50 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution by Eisai Inc.

Other drugs which contain Decitabine or a similar ingredient: (3 results)